At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LENZ Therapeutics
Trading 03-28 13:17:37 EDT
26.25
-0.28
-1.06%
| High27.78 | Low25.69 | Vol68.89K |
| Open26.35 | D1 Closing26.53 | Amplitude7.86% |
| Mkt Cap723.00M | Tradable Cap331.59M | Total Shares27.54M |
| T/O1.83M | T/O Rate0.55% | Tradable Shares12.63M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Silexion Therapeutics announces expanded development plan for SIL204
TIPRANKS · 12:41
Press Release: Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
Dow Jones · 12:30
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data
GlobeNewswire · 12:30
Plus Therapeutics Is Maintained at Buy by D. Boral Capital
Dow Jones · 11:35
ADC Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St. · 11:11
Q4 2024 Spero Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents · 11:10
Q4 2024 Relmada Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents · 11:05
Acrivon Therapeutics Price Target Maintained With a $19.00/Share by HC Wainwright & Co.
Dow Jones · 10:53
BofA Securities Upgrades Beam Therapeutics to Buy From Neutral
MT Newswires Live · 10:49
Promising Outlook for Plus Therapeutics: Strategic Financial Moves and Innovative Assay Launch Justify Buy Rating
TIPRANKS · 10:17
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
ACCESS Newswire · 00:15
Acrivon Therapeutics reports Q4 EPS (60c), consensus (70c)
TIPRANKS · 03-27 21:50
Press Release: Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
Dow Jones · 03-27 21:44
TransCode Therapeutics Starts Dosing for Experimental Cancer Treatment in Early Trial
MT Newswires Live · 03-27 21:32
Acrivon Therapeutics Reports 2024 Financial Results and Progress
TIPRANKS · 03-27 21:18
Beam Therapeutics New Drug Application for Alpha-1 Antitrypsin Deficiency Gets FDA Clearance
MT Newswires Live · 03-27 21:10
Relmada Therapeutics reports Q4 EPS (62c) vs. (84c) last year
TIPRANKS · 03-27 20:40
TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138
PR Newswire · 03-27 20:37
Spero Therapeutics reports Q4 EPS (38c), consensus (31c)
TIPRANKS · 03-27 20:20
Plus Therapeutics FY24 EPS $(1.95) Vs. $(4.24) YoY, Grant Revenue $5.8M Up From $4.9M YoY
Benzinga · 03-27 20:16
Introduction
Company Name.
Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
2021-06-25
Main Business:
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Issue price:
17.00
Invest in Global Markets with Tiger Brokers!Open App